Equities Analysts Set Expectations for BRTX FY2029 Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Research analysts at Roth Capital reduced their FY2029 EPS estimates for BioRestorative Therapies in a report issued on Friday, March 28th. Roth Capital analyst J. Aschoff now anticipates that the company will earn $6.86 per share for the year, down from their prior estimate of $6.93. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.43) per share.

BioRestorative Therapies (NASDAQ:BRTX) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.07. The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $0.48 million. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 98.49%.

BioRestorative Therapies Stock Performance

Shares of BRTX opened at $1.81 on Monday. BioRestorative Therapies has a 52 week low of $1.03 and a 52 week high of $2.55. The stock has a market capitalization of $12.53 million, a price-to-earnings ratio of -1.18 and a beta of 64.37. The stock has a fifty day moving average of $1.97 and a 200-day moving average of $1.73.

Hedge Funds Weigh In On BioRestorative Therapies

An institutional investor recently bought a new position in BioRestorative Therapies stock. Citadel Advisors LLC acquired a new stake in BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 21,481 shares of the company’s stock, valued at approximately $31,000. Citadel Advisors LLC owned 0.31% of BioRestorative Therapies at the end of the most recent reporting period. Hedge funds and other institutional investors own 69.38% of the company’s stock.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.